Thrombospondin 4 Activators

Lysophosphatidic acid (LPA) activates Thrombospondin 4 (THBS4) indirectly by binding to its G protein-coupled receptors LPAR1 and LPAR3. This activates the Rho/ROCK pathway, leading to increased THBS4 expression and secretion. Additionally, LPA stimulates the PI3K/Akt pathway, promoting THBS4 stability and preventing its degradation. These combined effects contribute to THBS4 activation.

A769662, an AMP-activated protein kinase (AMPK) activator, indirectly activates THBS4 by modulating cellular energy status. AMPK activation by A769662 inhibits mTOR signaling, relieving its suppressive effect on THBS4 transcription. Moreover, activated AMPK stabilizes THBS4 mRNA and enhances its translation, leading to increased THBS4 levels in the cellular milieu. This dual regulatory mechanism positions A769662 as a potent indirect activator of THBS4.

Trichostatin A, a histone deacetylase (HDAC) inhibitor, indirectly activates THBS4 by epigenetically modulating its gene expression. By inhibiting HDACs, trichostatin A promotes histone acetylation at the THBS4 promoter region, facilitating transcription. This epigenetic modification enhances the accessibility of transcriptional machinery, resulting in increased THBS4 mRNA synthesis and subsequent protein activation.

Dibutyryl cAMP, a cell-permeable analog of cyclic AMP (cAMP), indirectly activates THBS4 by stimulating the cAMP/PKA signaling pathway. Activation of PKA by dibutyryl cAMP leads to phosphorylation of CREB, which binds to the THBS4 promoter, enhancing its transcription. Additionally, cAMP/PKA signaling regulates THBS4 at the post-translational level, influencing its stability and secretion. These concerted effects contribute to the activation of THBS4 by dibutyryl cAMP.

SB203580, a p38 MAPK inhibitor, indirectly activates THBS4 by relieving the inhibitory effect of p38 MAPK on its expression. Inhibition of p38 MAPK by SB203580 attenuates the downstream signaling cascade that negatively regulates THBS4 transcription. Furthermore, SB203580 disrupts the feedback loop involving p38 MAPK and THBS4, resulting in increased THBS4 levels. This indirect activation highlights the intricate interplay between p38 MAPK signaling and THBS4 regulation.

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, indirectly activates THBS4 by modulating PPAR-γ signaling. Activation of PPAR-γ by rosiglitazone enhances its binding to the THBS4 promoter, promoting transcription. Additionally, PPAR-γ activation influences THBS4 at the post-translational level, impacting its stability and secretion. These combined effects position rosiglitazone as a potent indirect activator of THBS4.

Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly activates THBS4 by disrupting the PI3K/Akt signaling pathway. Inhibition of PI3K by wortmannin reduces Akt phosphorylation, relieving its inhibitory effect on THBS4 expression. Moreover, wortmannin affects THBS4 at the post-translational level, modulating its stability and secretion. These dual regulatory mechanisms contribute to the indirect activation of THBS4 by wortmannin.

SP600125, a JNK inhibitor, indirectly activates THBS4 by inhibiting the c-Jun N-terminal kinase (JNK) signaling pathway. Inhibition of JNK by SP600125 attenuates its suppressive effect on THBS4 expression, promoting its transcription. Additionally, SP600125 disrupts the feedback loop involving JNK and THBS4, resulting in increased THBS4 levels. This dual regulatory mechanism positions SP600125 as an effective indirect activator of THBS4.

Bay 11-7082, an NF-κB inhibitor, indirectly activates THBS4 by modulating the NF-κB signaling pathway. Inhibition of NF-κB by Bay 11-7082 relieves its suppressive effect on THBS4 expression, promoting transcription. Furthermore, Bay 11-7082 disrupts the NF-κB-THBS4 feedback loop, resulting in increased THBS4 levels. These combined effects position Bay 11-7082 as a potent indirect activator of THBS4.

Forskolin, an adenylate cyclase activator, indirectly activates THBS4 by stimulating the cAMP/PKA signaling pathway. Activation of PKA by forskolin leads to CREB phosphorylation, facilitating its binding to the THBS4 promoter and enhancing transcription. Additionally, forskolin influences THBS4 at the post-translational level, impacting its stability and secretion. These concerted effects contribute to the indirect activation of THBS4 by forskolin.